Total Funding
57
36
Total FundingCorporate Round raised
Growth Score
-7 pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
44170
STALICLA is a biopharmaceutical company that develops precision medicine for neurodevelopmental and neuropsychiatric disorders.
- Lynn Durham: CEO
- Baltazar Gomez-Mancilla: Chief Medical Officer
About the Company
Stalicla is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.
Stalicla’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible
biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.
